홈 > 시장보고서 > 의약품 > 파이프라인 분석

시장보고서

상품코드

2013102

맥락막결손증 시장 : 치료법별, 투여 경로별, 환자층별, 병기별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2026-2033년)

Choroideremia Market, By Treatment Type, By Route of Administration, By Patient Demographics, By Disease Stage, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: 2026년 03월 | 리서치사: 구분자

AnalystView Market Insights | 페이지 정보: 영문 304 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 3,250

￦ 4,748,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,650

￦ 6,793,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650

￦ 8,254,000

※ 부가세 별도

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

맥락막결손증 시장 규모는 2025년에 97억 8,595만 달러로 평가되었으며, 2026년부터 2033년까지 CAGR 4.87%로 확대될 것으로 전망됩니다.

맥락막결손증은 주로 남성에게 발병하며 서서히 시력 저하를 유발하는 희귀한 유전성 안질환입니다. 어두운 곳에서의 시력저하로 시작하여 점차 주변시력, 중심시력, 결국 중심시력 상실로 진행되어 실명에 이르기도 합니다. 주로 남성에게 발병합니다. 미국 국립보건원(NIH)의 정부 자료에 따르면, 발병률은 약 5만-10만 명 중 1명꼴로 실명 사례의 일부를 차지합니다. 맥락막결손증 시장은 이 희귀 안질환의 치료법, 특히 유전자 치료와 같은 새로운 치료법의 개발 및 판매와 관련된 비즈니스를 의미합니다. 환자 수는 극소수이지만, 기업이 조사개발에 더 많은 투자를 하고 새로운 치료법이 개발되고 있고, 시간이 지남에 따라 시력 저하를 실제로 지연시키거나 멈출 수 있는 치료법에 대한 명확한 요구가 있기 때문에 시장은 여전히 확대되고 있습니다.

맥락막결손증 시장 - 시장 역학

유전자 치료제 개발에 대한 관심 증가

맥락막결손증 시장을 견인하는 주요 요인은 정부의 지원과 규제 혜택에 힘입어 유전자 치료제 개발이 확대되고 있습니다. 미국 국립보건원(NIH)은 치료 옵션이 제한적인 희귀질환에 대한 자금 지원과 이니셔티브를 통해 유전자 치료 프로그램을 추진하고 있습니다. 맥락막결손증은 단일 유전자 돌연변이에 의해 발생하기 때문에 유전자 대체 요법에 적합하며, 정부 지원 연구를 통해 이러한 치료법은 이미 임상시험 단계에 이르렀고 환자에게 명백한 혜택을 가져다주었습니다. Biogen Inc., Spark Therapeutics, REGENXBIO Inc. 등의 기업들이 이러한 치료제 개발에 적극 나서고 있습니다. 또한, 미국 식품의약국(FDA)은 희귀질환 치료제 지정 및 희귀질환 지정을 통해 기업들이 보다 신속하게 개발을 진행할 수 있도록 지원하고 있습니다. 이는 연구 활동과 시장 성장을 직접적으로 촉진하고 있습니다.

맥락막결손증 시장 - 시장 세분화 분석:

세계 맥락막결손증 시장은 치료법, 투여 경로, 환자군, 질병 진행 단계, 최종사용자 및 지역에 따라 세분화되어 있습니다.

치료법 유형에 따라 시장은 유전자 치료, 외과적 개입, 약물 치료, 증상 치료, 세포 치료, 약물 치료, 약물 치료의 6개 부문으로 나뉩니다. 유전자 치료는 이 시장에서 가장 중요한 위치를 차지하고 있습니다. 왜냐하면 질병의 주요 원인인 손상된 CHM 유전자를 직접 복구하는 반면, 약물이나 수술과 같은 다른 대안은 증상 조절에 그치고 시력 저하를 막을 수 없기 때문입니다. 이 질환은 약 5만-10만 명 중 1명꼴로 발병하는 매우 희귀한 질환으로 각국 정부는 이를 희귀질환으로 분류하고 희귀질환 치료제 프로그램 및 연구비를 통해 개발을 지원하고 있습니다. 유전자 치료는 바이러스 벡터(AAV 등)를 이용해 기능하는 유전자를 망막세포에 도입하는 방식으로, 이미 임상시험을 통해 일부 환자에서 시력 유지 또는 개선이 확인된 바 있습니다. 유전자 치료는 일회성 치료법이며, 근본적인 문제를 해결하고, 확실한 임상 결과를 보여주기 때문에 자금, 임상시험, 규제 당국의 관심의 대부분이 유전자 치료에 집중되고 있으며, 가장 널리 채택되고 있는 분야입니다.

투여 경로의 관점에서 볼 때, 시장은 4개의 부문으로 나뉩니다. 즉, 망막하 주사, 유리체강내 주사, 경구 투여, 정맥내 투여가 있습니다. 망막하 주사는 질병이 발생한 손상된 망막 세포에 직접 유전자 치료제를 전달하기 때문에 맥락막결손증 시장에서 중심적인 역할을 할 것으로 예상됩니다. 정부 지원 임상 조사에 따르면, 맥락막결손증에 대한 유전자 치료는 주로 망막하 투여를 통해 이루어지고 있으며, 이는 망막 색소상피와 광수용체를 직접 표적으로 하는 AAV(아데노 부속 바이러스) 기반 치료법을 이용한 임상시험에서도 확인할 수 있습니다. 과학적 연구에서도 망막하 주사는 다른 투여 경로에 비해 더 정확하고 효과적인 전달이 가능하며, 표적 부위에서의 약물 농도를 증가시키는 것으로 확인되었습니다. 이 접근법은 망막에 직접 전달이 필요한 AAV 기반 치료에 초점을 맞추고 있는 Spark Therapeutics와 REGENXBIO Inc. 이 부문의 주요 특징으로는 표적 유전자 도입, 치료 효과의 향상, 일회성 치료에 대한 적합성 등이 있으며, 유리체강 내 주사와 같은 대체 방법보다 더 침습적임에도 불구하고 가장 널리 채택된 경로가 되었습니다.

맥락막결손증 시장 - 지역별 분석

북미에서는 강력한 연구 기반과 희귀질환 치료에 대한 정부의 일관된 지원으로 인해 맥락막결손증 시장이 괄목할 만한 성장을 기록할 것으로 예상됩니다. 미국 국립보건원(NIH)은 유전성 망막질환을 대상으로 한 여러 유전자 치료 프로그램에 자금을 지원하여 초기 단계의 연구부터 임상연구까지 지원하고 있습니다. 한편, 미국 식품의약국(FDA)은 치료법 개발을 가속화하기 위해 희귀질환 치료제로 지정하고 있습니다. 미국 정부 지원 연구는 Spark Therapeutics, REGENXBIO 등의 기업의 지원을 받아 시력 측정이 가능한 맥락막 망막위축증에 대한 유전자 치료제를 이미 인간 임상시험 단계까지 진행하고 있습니다. 유럽은 활발한 임상 연구와 공공 의료 시스템의 참여에 힘입어 다음 중요한 지역으로 부상하고 있습니다. 영국에서는 영국 보건부의 자금 지원을 포함한 정부 주도의 임상시험이 망막하 유전자 치료의 초기 단계 인체 시험에 기여하고 있으며, 진행 중인 연구와 환자 접근을 지원하는 체계적인 희귀질환 정책도 마련돼 있습니다.

캐나다 맥락막결손증 시장 - 국가별 인사이트

캐나다는 정부의 꾸준한 연구 지원과 희귀 안질환에 대한 뚜렷한 의료적 관심으로 인해 맥락막결손증 시장에서 중요한 국가로 부상하고 있습니다. "Fighting Blindness Canada(Fighting Blindness Canada) 등의 단체에서 제공하는 데이터에 따르면, 캐나다에는 약 21,000명이 맥락막결손증을 포함한 유전성 망막질환을 앓고 있으며, 장기적인 관리와 치료를 필요로 하는 뚜렷한 환자층이 존재한다고 합니다. 층이 존재하는 것으로 나타났습니다. 또한, 캐나다의 정부 관련 임상 연구에 따르면, 이들 질환을 앓고 있는 환자의 68% 이상이 법적으로 시각장애인이라는 사실이 밝혀져 심각한 의료비 부담과 효과적인 치료법이 필요함을 보여주고 있습니다. 또한, 캐나다에서는 학계와 임상 현장의 참여가 활발히 이루어지고 있으며, 앨버타 대학교와 같은 기관이 유전학 연구와 맥락막결손증 진단에 기여하고 있습니다. 유전자 기반 접근법을 연구하는 기업 및 연구 그룹은 공공 의료 시스템 및 세계 생명공학 기업과의 협력을 통해 지원을 받고 있습니다. 전반적으로, 캐나다의 체계적인 의료 시스템, 지속적인 연구 활동, 그리고 명확하게 식별된 환자 집단은 안정적이고 체계적인 형태로 새로운 치료법의 개발 및 도입을 뒷받침하고 있습니다.

Choroideremia is a rare inherited eye disease that mainly affects males and slowly causes vision loss. It starts with difficulty seeing in the dark and gradually leads to loss of side vision and eventually central vision, sometimes resulting in blindness. It mainly affects males. According to government data from the U.S. National Institutes of Health, it affects about 1 in 50,000 to 100,000 people and contributes to a portion of blindness cases. The choroideremia market is the business around making and selling treatments for this rare eye disease, especially newer options like gene therapy. Even though very few people have it, the market is still expanding because companies are investing more in research, new treatment methods are being developed, and there is a clear need for treatments that can actually slow down or stop vision loss over time.

Choroideremia Market- Market Dynamics

Increasing Emphasis on Gene Therapy Development

A key factor driving the choroideremia market is the increasing development of gene therapy, backed by government support and regulatory incentives. The National Institutes of Health promotes gene therapy programs for rare diseases through funding and initiatives, as these conditions often have limited treatment options. Since choroideremia is caused by a single gene mutation, it is well suited for gene replacement approaches, and government-supported studies have already pushed these therapies into clinical trials with visible patient benefits. Companies like Biogen Inc., Spark Therapeutics, and REGENXBIO Inc. are actively working on such treatments. In addition, the U.S. Food and Drug Administration offers orphan drug and rare disease designations, helping companies move faster, which directly increases research activity and market growth.

Choroideremia Market- Segmentation Analysis:

The Global Choroideremia Market is segmented on the basis of Treatment Type, Route of Administration, Patient Demographics, Disease Stage, End User, and Region.

The market is split into six segments according to treatment type: Gene Therapy, Surgical Intervention, Pharmacological Treatment, Symptomatic Treatment, Cell Therapy, and Drug Therapy. Gene therapy is the most important part of this market because it directly fixes the main cause of the disease, the damaged CHM gene, while other options, like drugs or surgery, only manage symptoms and cannot stop vision loss. This disease is very rare, affecting roughly 1 in 50,000 to 100,000 people, which is why governments classify it under rare diseases and support development through orphan drug programs and research funding. Gene therapy stands out because it uses viral vectors (like AAV) to deliver a working gene into retinal cells, and clinical trials have already shown maintained or improved vision in some patients. Because it offers a one-time treatment approach, targets the root problem, and shows real clinical results, most funding, trials, and regulatory attention are focused on gene therapy, making it the most widely adopted segment.

The market is structured into four segments in terms of Route of Administration: Subretinal Injection, Intravitreal Injection, Oral Route, and Intravenous Route. The subretinal injection is anticipated to play a central role in the choroideremia market because it delivers gene therapy directly to the damaged retinal cells where the disease occurs. Government-supported clinical research shows that gene therapies for choroideremia are primarily administered through subretinal delivery, as seen in trials using AAV-based treatments that directly target the retinal pigment epithelium and photoreceptors. Scientific studies also confirm that subretinal injection provides more precise and effective delivery compared to other routes, ensuring higher drug concentration at the target site. This approach is widely used by companies such as Spark Therapeutics and REGENXBIO Inc., which focus on AAV-based therapies requiring direct retinal delivery. Key features of this segment include targeted gene transfer, improved treatment effectiveness, and suitability for one-time therapy, which makes it the most widely adopted route despite being more invasive than alternatives like intravitreal injection.

Choroideremia Market- Geographical Insights

North America is forecasted to register meaningful growth of the choroideremia market due to its strong research base and consistent government support for rare disease therapies. The National Institutes of Health funds multiple gene therapy programs for inherited retinal diseases, supporting both early-stage and clinical research, while the U.S. Food and Drug Administration provides orphan drug designations that help speed up treatment development. Government-backed studies in the U.S. have already advanced gene therapy for choroideremia into human trials with measurable vision improvements, supported by companies such as Spark Therapeutics and REGENXBIO Inc. Europe represents the next significant region, supported by active clinical research and public healthcare involvement, where government-backed trials in the United Kingdom, including funding from the UK Department of Health, have contributed to early human studies of subretinal gene therapy, along with structured rare disease policies that support ongoing research and patient access.

Canada Choroideremia Market- Country Insights

Canada represents an important country in the choroideremia market due to steady government-supported research and a clear healthcare focus on rare eye diseases. According to data supported by organizations like Fighting Blindness Canada, around 21,000 Canadians are living with inherited retinal diseases, including choroideremia, showing a defined patient base that requires long-term care and treatment. In addition, government-linked clinical studies in Canada highlight that over 68% of patients with these conditions are legally blind, indicating a serious healthcare burden and the need for effective therapies. The country also has strong academic and clinical involvement, with institutions such as the University of Alberta contributing to genetic research and the diagnosis of choroideremia. Companies and research groups working with gene-based approaches are supported through public healthcare systems and collaborations with global biotech firms. Overall, Canada's structured healthcare system, ongoing research efforts, and clearly identified patient population support continued development and adoption of new treatments in a stable and organized manner.

Choroideremia Market- Competitive Landscape:

The competitive landscape of the choroideremia market is shaped by a group of biotechnology and pharmaceutical companies focusing on gene-based treatments, as there are limited approved options and ongoing clinical development. Key players include Biogen Inc., Spark Therapeutics, REGENXBIO Inc., MeiraGTx Holdings plc, and 4D Molecular Therapeutics, all working on AAV-based gene therapies targeting the underlying genetic cause. Government-supported clinical data show that multiple gene therapy trials for choroideremia have already progressed to Phase I, II, and III stages across the U.S., UK, and other regions, indicating steady development activity. In addition, public research funding from institutions such as the National Institute for Health and Care Research in the UK and similar government bodies supports clinical studies and infrastructure for these trials. The market remains research-driven, with companies focusing on clinical trial advancement, regulatory approvals, and long-term treatment outcomes, as gene therapy continues to be the primary area of development.

Recent Developments:

In October 2025, DelveInsight and other industry pipeline insights highlighted expanding clinical research and multi-modal approaches (gene therapy, gene editing, RNA-based therapies, optogenetics) advancing through preclinical and clinical stages for choroideremia, signaling broadening therapeutic research activity. This trend reflects a gradual shift toward more diverse treatment strategies, with multiple technologies being explored to address the disease from different angles, indicating steady progress in development efforts and a wider scope for future therapeutic options.

In June 2025, the Choroideremia Research Foundation awarded six new global research grants to accelerate vision science and treatment innovation in choroideremia, funding projects including CRISPR-based gene editing and long-term gene therapy follow-up studies. This reflects continued financial and scientific support for advanced research approaches, with a clear focus on improving long-term treatment outcomes and expanding the scope of therapeutic development for the condition.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOROIDEREMIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

MeiraGTx Limited (U.K.)
REGENXBIO (U.S.)
GenSight Biologics (France)
Editas Medicine (U.S.)
Spark Therapeutics (U.S.)
Sangamo Therapeutics (U.S.)
CRISPR Therapeutics AG (Switzerland)
Nanoscope Therapeutics, Inc. (U.S.)
4D Molecular Therapeutics (U.S.)
ProQR Therapeutics N.V. (Netherlands)
Horama SA (France)
Homology Medicines, Inc. (U.S.)
Beacon Therapeutics (U.S.)
Eyevensys (Switzerland)
Visgenx (U.S.)
Atsena Therapeutics Inc. (U.S.)
Coave Therapeutics (U.S.)
Neurophth Therapeutics (China)
Johnson & Johnson Services, Inc. (U.S.)
Ocugen, Inc. (U.S.)

GLOBAL CHOROIDEREMIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

Gene Therapy
Surgical Intervention
Pharmacological Treatment
Symptomatic Treatment
Cell Therapy
Drug Therapy

GLOBAL CHOROIDEREMIA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

Subretinal Injection
Intravitreal Injection
Oral Route
Intravenous Route

GLOBAL CHOROIDEREMIA MARKET, BY PATIENT DEMOGRAPHICS- MARKET ANALYSIS, 2020 - 2033

Pediatric Patients
Adult Patients
Geriatric Patients

GLOBAL CHOROIDEREMIA MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2020 - 2033

Early Stage
Mid Stage
Late Stage

GLOBAL CHOROIDEREMIA MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

Hospitals
Specialty Ophthalmology Clinics
Ambulatory Surgical Centers
Research & Academic Institutes
Homecare Settings

GLOBAL CHOROIDEREMIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Choroideremia Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Choroideremia Market Snippet by Treatment Type
- 2.1.2. Choroideremia Market Snippet by Route of Administration
- 2.1.3. Choroideremia Market Snippet by Patient Demographics
- 2.1.4. Choroideremia Market Snippet by Disease Stage
- 2.1.5. Choroideremia Market Snippet by End User
- 2.1.6. Choroideremia Market Snippet by Country
- 2.1.7. Choroideremia Market Snippet by Region
2.2. Competitive Insights

3. Choroideremia Key Market Trends

3.1. Choroideremia Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Choroideremia Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Choroideremia Market Opportunities
3.4. Choroideremia Market Future Trends

4. Choroideremia Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Choroideremia Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Choroideremia Market Landscape

6.1. Choroideremia Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Choroideremia Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
- 7.1.2. Gene Therapy
- 7.1.3. Surgical Intervention
- 7.1.4. Pharmacological Treatment
- 7.1.5. Symptomatic Treatment
- 7.1.6. Cell Therapy
- 7.1.7. Drug Therapy

8. Choroideremia Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 8.1.2. Subretinal Injection
- 8.1.3. Intravitreal Injection
- 8.1.4. Oral Route
- 8.1.5. Intravenous Route

9. Choroideremia Market - By Patient Demographics

9.1. Overview
- 9.1.1. Segment Share Analysis, By Patient Demographics, 2025 & 2033 (%)
- 9.1.2. Pediatric Patients
- 9.1.3. Adult Patients
- 9.1.4. Geriatric Patients

10. Choroideremia Market - By Disease Stage

10.1. Overview
- 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 10.1.2. Early Stage
- 10.1.3. Mid Stage
- 10.1.4. Late Stage

11. Choroideremia Market - By End User

11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 11.1.2. Hospitals
- 11.1.3. Specialty Ophthalmology Clinics
- 11.1.4. Ambulatory Surgical Centers
- 11.1.5. Research & Academic Institutes
- 11.1.6. Homecare Settings

12. Choroideremia Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Choroideremia Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Choroideremia Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Choroideremia Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Choroideremia Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Choroideremia Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Choroideremia Industry

13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. MeiraGTx Limited (U.K.)
- 13.2.2. REGENXBIO (U.S.)
- 13.2.3. GenSight Biologics (France)
- 13.2.4. Editas Medicine (U.S.)
- 13.2.5. Spark Therapeutics (U.S.)
- 13.2.6. Sangamo Therapeutics (U.S.)
- 13.2.7. CRISPR Therapeutics AG (Switzerland)
- 13.2.8. Nanoscope Therapeutics, Inc. (U.S.)
- 13.2.9. 4D Molecular Therapeutics (U.S.)
- 13.2.10. ProQR Therapeutics N.V. (Netherlands)
- 13.2.11. Horama SA (France)
- 13.2.12. Homology Medicines, Inc. (U.S.)
- 13.2.13. Beacon Therapeutics (U.S.)
- 13.2.14. Eyevensys (Switzerland)
- 13.2.15. Visgenx (U.S.)
- 13.2.16. Atsena Therapeutics Inc. (U.S.)
- 13.2.17. Coave Therapeutics (U.S.)
- 13.2.18. Neurophth Therapeutics (China)
- 13.2.19. Johnson & Johnson Services, Inc. (U.S.)
- 13.2.20. Ocugen, Inc. (U.S.)

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격